Tuesday November 19, 10:40 am ET
HealthBridge, a reimbursement and product support services company, was selected by Biogen, Inc. to offer funding research services for AVONEX® (Interferon beta-1a) which is indicated for the treatment of relapsing forms of Multiple Sclerosis. The Funding Research Group works with uninsured and underinsured patients to help them obtain adequate coverage for AVONEX therapy, and also works with Medicare patients to help them enroll in supplemental policies that will compliment existing Medicare coverage of AVONEX.
Biogen, Inc. announced in May that Medicare would now provide coverage for multiple sclerosis patients treated with AVONEX as part of physician services. The action by the Center for Medicare and Medicaid Services (CMS) implements a law passed by Congress to restore Medicare coverage for certain injectable prescription medicines.
"We are very pleased to have been chosen by Biogen to seek additional coverage for MS patients," stated John J. Seman, President & CEO of HealthBridge. "The services offered by the Funding Research Group have proven to be of high value to a large patient population who otherwise might not be able to access therapy."
HealthBridge Reimbursement and Product Support, Inc. is a dynamic, growth- oriented company with a vision to continuously evolve services, which simplify the complexities of medical reimbursement. They provide pharmaceutical and biotechnology companies with innovative reimbursement solutions that support product goals and help ensure market success. HealthBridge is located in Braintree, Massachusetts. For more information, please visit www.healthbridgeinc.com.
Contact: Stacie Madden - (781) 926-3614
Copyright © 2002 PR Newswire